IL6 and neoplasm: Moreover, inhibiting their signaling with anti-IL-6R and CSF1Ri kept CD14+ cDC2 frequencies equal to tumor-free conditions, underlining IL-6 and M-CSF as dominant drivers of tumor-induced CD14+ cDC2s.